Letermovir for the compassionate therapeutic use of cytomegalovirus infection.
Compassionate therapeutic use
Cytomegalovirus infection
Letermovir
Viral kinetics
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
16
05
2020
accepted:
15
07
2020
pubmed:
12
9
2020
medline:
24
7
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited. Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections. Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%). Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
Identifiants
pubmed: 32914220
doi: 10.1007/s10096-020-03990-w
pii: 10.1007/s10096-020-03990-w
pmc: PMC7817558
doi:
Substances chimiques
Acetates
0
Antiviral Agents
0
Quinazolines
0
letermovir
1H09Y5WO1F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-439Références
Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L et al (2018) The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900–931. https://doi.org/10.1097/TP.0000000000002191
doi: 10.1097/TP.0000000000002191
pubmed: 29596116
Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689–712. https://doi.org/10.1128/CMR.00009-10
doi: 10.1128/CMR.00009-10
pubmed: 20930070
pmcid: 2952978
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433–2444. https://doi.org/10.1056/NEJMoa1706640
doi: 10.1056/NEJMoa1706640
pubmed: 29211658
Ligat G, Cazal R, Hantz S, Alain S (2018) The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev 42:137–145. https://doi.org/10.1093/femsre/fuy004
doi: 10.1093/femsre/fuy004
pubmed: 29361041
pmcid: 5972660
Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P et al (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:1079–1084. https://doi.org/10.1111/j.1600-6143.2011.03530.x
doi: 10.1111/j.1600-6143.2011.03530.x
pubmed: 21521474
Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW et al (2019) Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02337-18
Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D et al (2020) Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. https://doi.org/10.1097/TP.0000000000002785
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G et al (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. https://doi.org/10.1093/cid/ciw668
Humar A, Kumar D, Boivin G, Caliendo AM (2002) Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186:829–833. https://doi.org/10.1086/342601
doi: 10.1086/342601
pubmed: 12198618
Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S (2018) Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 18:3060–3064. https://doi.org/10.1111/ajt.15135
doi: 10.1111/ajt.15135
pubmed: 30286286
pmcid: 6263820
Lischka P, Michel D, Zimmermann H (2016) Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 213:23–30. https://doi.org/10.1093/infdis/jiv352
doi: 10.1093/infdis/jiv352
pubmed: 26113373
Jung S, Michel M, Stamminger T, Michel D (2019) Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis 19. https://doi.org/10.1186/s12879-019-4016-1
Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M et al (2020) Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis. https://doi.org/10.1093/infdis/jiz577
Stoelben S, Arns W, Renders L, Hummel J, Mühlfeld A, Stangl M et al (2014) Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 27:77–86. https://doi.org/10.1111/tri.12225
doi: 10.1111/tri.12225
pubmed: 24164420